Presepsin as a Diagnostic Biomarker Across Clinical Settings: From ICU Sepsis to Neonatal and Orthopedic Infections
This review surveys presepsin applications across diverse clinical settings including intensive care, neonatal sepsis, orthopedic infections, pulmonary infections, fungal infections, and endocarditis. As a soluble fragment of CD14 that rises with monocyte phagocytic activation, presepsin offers faster kinetics than CRP and comparable performance to procalcitonin in many contexts. The breadth of clinical evidence positions presepsin as a versatile addition to the infection biomarker panel, though standardization and cut-off validation remain ongoing challenges.
The original study
Clinical application of presepsin as diagnostic biomarker of infection: overview and updates.
- Authors
- Galliera E, Massaccesi L, de Vecchi E, Banfi G, Romanelli MMC
- Journal
- Clinical chemistry and laboratory medicine
- Type
- Journal Article, Review
- PMID
- 31421036
Original abstract
The appropriate identification of bacterial infection is the basis for effective treatment and control of infective disease. Among this context, an emerging biomarker of infection is presepsin (PSP), recently described as early marker of different infections. PSP secretion has been shown to be associated with monocyte phagocytosis and plasmatic levels of PSP increase in response to bacterial infection and decrease after antibiotic treatment, therefore it can be considered a marker of activation of immune cell response towards an invading pathogen. Different methods have been developed to measure PSP and this review will briefly describe the different clinical fields of application of PSP, ranging from intensive care to neonatal infection, to orthopedic and pulmonary infection as well as fungal infections and cardiovascular infections.